Brii Biosciences Limited (HKG:2137)
Hong Kong · Delayed Price · Currency is HKD 0.9600
-0.0700 (-6.80%)
Aug 27, 2026, 4:08 PM HKT
Brii Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 18.61 | 18.61 | - | 0.62 | 51.63 | - |
Other Revenue | 16.25 | 16.94 | 49.94 | 55.27 | 70.65 | 92.54 |
| 34.85 | 35.55 | 49.94 | 55.89 | 122.28 | 92.54 | |
Revenue Growth | 21.12% | -28.81% | -10.66% | -54.29% | 32.13% | 12.56% |
Gross Profit | 34.85 | 35.55 | 49.94 | 55.89 | 122.28 | 92.54 |
Selling, General & Admin | 103.8 | 109.45 | 153.16 | 197.92 | 195.49 | 208.4 |
Research & Development | 194.21 | 212.9 | 249.85 | 402.71 | 440.63 | 494.62 |
Operating Expenses | 298.01 | 322.35 | 453.79 | 600.62 | 636.12 | 703.02 |
Operating Income | -263.16 | -286.8 | -403.85 | -544.73 | -513.85 | -610.48 |
Interest Expense | -0.19 | -1.96 | -2.37 | -0.49 | -0.85 | -1.18 |
Interest & Investment Income | 43.62 | 51.54 | 87.15 | 108.02 | 37.2 | 6.49 |
Currency Exchange Gain (Loss) | 1.9 | 1.9 | 1.67 | 121.59 | -43.98 | 0.27 |
Other Non Operating Income (Expenses) | 29.96 | -0.42 | 5.06 | 0.43 | - | - |
EBT Excluding Unusual Items | -187.88 | -235.75 | -312.34 | -315.18 | -521.47 | -604.9 |
Gain (Loss) on Sale of Investments | 13.99 | 13.99 | -109.69 | 136.24 | 31.69 | 44.8 |
Gain (Loss) on Sale of Assets | -0.41 | -0.41 | - | - | - | - |
Asset Writedown | - | - | -90.35 | -5.43 | - | - |
Other Unusual Items | - | - | - | - | - | -3,631 |
Pretax Income | -174.3 | -222.17 | -512.38 | -184.37 | -489.78 | -4,191 |
Income Tax Expense | 1.9 | 1.9 | - | - | - | - |
Earnings From Continuing Operations | -176.2 | -224.07 | -512.38 | -184.37 | -489.78 | -4,191 |
Minority Interest in Earnings | 1.08 | 1.44 | 4.22 | 9.54 | 5.47 | 27.24 |
Net Income | -175.12 | -222.62 | -508.16 | -174.83 | -484.31 | -4,164 |
Net Income to Common | -175.12 | -222.62 | -508.16 | -174.83 | -484.31 | -4,164 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 727 | 722 | 730 | 728 | 723 | 439 |
Shares Outstanding (Diluted) | 727 | 722 | 730 | 728 | 723 | 439 |
Shares Change | 0.02% | -1.15% | 0.29% | 0.64% | 64.78% | 129.57% |
EPS (Basic) | -0.24 | -0.31 | -0.70 | -0.24 | -0.67 | -9.48 |
EPS (Diluted) | -0.24 | -0.31 | -0.70 | -0.24 | -0.67 | -9.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -340.46 | -376.12 | -594.01 | -496.28 | -880.49 |
Free Cash Flow Per Share | - | -0.47 | -0.52 | -0.82 | -0.69 | -2.00 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -755.10% | -806.80% | -808.74% | -974.63% | -420.22% | -659.68% |
Profit Margin | -502.48% | -626.26% | -1017.63% | -312.80% | -396.07% | -4499.41% |
Free Cash Flow Margin | - | -957.76% | -753.20% | -1062.81% | -405.86% | -951.45% |
EBITDA | -262.51 | -286.14 | -401.61 | -538.15 | -505.9 | -602.8 |
D&A For EBITDA | 0.66 | 0.66 | 2.25 | 6.59 | 7.94 | 7.68 |
EBIT | -263.16 | -286.8 | -403.85 | -544.73 | -513.85 | -610.48 |